Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference

NOVATO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will present at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12, 2017 at 10:00 am ET in New York, NY.

The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company has rapidly built and advanced a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Ryan Martins 
415-483-8257

Source: Ultragenyx Pharmaceutical Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Increasing unusual put option volume: ITB RARE XLY CARR FRVO XME TRIP CPNG RCL TECK MXEF
• Como elegir una firma de fondeo en 2026: lo que el trader deberia exigir antes de pagar una evaluacion
• How to choose a funding firm in 2026: what traders should demand before paying for an evaluation